Company: APXIF
Filing Date: 2025-07-03
Form Type: F-4/A
Source: 0001213900-25-061545
Chunk: 276

Company: APx Acquisition Corp. I
Filing Date: 2025-07-03
Form: F-4/A
Chunk 276
---
field, as borrower, entered into the Sponsor Loan Agreement. The Sponsor Loan Agreement was amended on September 6, 2023 to increase the credit line from $250,000 to $275,000; on October 12, 2023 to increase the credit line to $400,000; on November 9, 2023 to increase the credit line to $1,000,000; and on March 25, 2024 to increase the credit line to $2,000,000. On March 25, 2024, the parties entered into a fourth amendment to the Sponsor Loan Agreement, pursuant to which certain commercial conditions were amended, including the placement of a legend on 700,000 SPAC Ordinary Shares owned by the Sponsor and changes to the maturity date. The Sponsor Loan Agreement accrues interest at 11% per annum and matures either on the first, second or third anniversary of the closing of the Business Combination, according to certain thresholds related to the volume weighted average price of Company Shares on such dates. Mr. Bransfield, as borrower, also entered into a pledge and security agreement, with Bioceres Group PLC, as the lender, and UG Holdings LLC, as the pledgor, pursuant to which, in order to secure his obligations under the Sponsor Loan Agreement, he pledged 100,000 ordinary shares of Moolec Science SA as security. For more information, see “ — Certain Agreements Related to the Business Combination.” 125 During the week of August 21, 2023, representatives of OmnigenicsAI and MultiplAI had a series of meetings to discuss details of both companies, products, organization, and future plans as a public company. Talks of a potential deal came into place, where a new surviving company would be formed with three business units: Rewell, MultiplAI, and Heritas. On August 28, 2023, representatives of OmnigenicsAI and MultiplAI had a meeting with Linklaters LLP (“Linklaters”) to discuss a potential business combination with APx and the MultiplAI Acquisition and began negotiations to formally engage Linklaters as its external legal counsel to assist it in a potential share purchase agreement in respect of the MultiplAI Acquisition and business combination transaction with APx. The engagement letter was executed on September 18, 2023. The shareholder vote for APx was set for September 1, 2023 to vote on the purchase agreement of Sponsor and APx. On September 8